The Reticulum Cell Sarcoma (RCS)' is a spontaneous lymphatic tumor of the SJL/J (H-29) mouse, first observed by Murphy (1) in upwards of 90% of SJL/J mice of a mean age of 13 .3 mo. RCS tumors are considered B cell lineage neoplasms that exhibit Ig H chain gene rearrangements, but no surface or cytoplasmic Ig (2). Additionally, RCS tumors express IAs MHC-encoded polypeptides (3). RCS tumors require an obligate syngeneic host CD4+ T cell response for growth (4, 5) 
Evidence is presented that supports a major role for KJ23a+ T cells in the response to both spontaneous and transplantable RCS tumors.
Materials and Methods
Mice. Female SJL/J, DBA/2, and BALB/c mice (6-8 wk) were purchased from TheJackson Laboratory, Bar Harbor, ME. BALB/c nu/nu mice were bred in the nude mice facility at UCLA, Los Angeles, CA.
Medium . All cultures were performed in high glucose formula DMEM (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS (Gemini Bio-Products, Calabasas, CA), sodium pyruvate, nonessential amino acids, L-glutamine, penicillin, streptomycin (all from Gibco Laboratories), and 5 x 10-5 M 2-ME (Sigma Chemical Co., St. Louis, MO) .
mAbs. The KJ23-588.1 (KJ23a), MIgG2a, hybridoma specific for Vp17a TCR bearing T cells, as described (11) , was the generous gift of Drs . P. Marrack and J. Kappler (National Jewish Center for Immunology and Respiratory Medicine, Denver, CO) . KJ23a mAb was purified from ascites fluid of BALB/c mice using protein A-agarose (Bio-Rad Laboratories, Richmond, CA) . F23 .1.R2 (F23.1), MIgG2a, hybridoma specific for V(D8 TCRbearing T cells, as described (13) , was the generous gift of Dr. E. Sercarz (UCLA, Los Angeles, CA) . F23 .1 was purified from ascites fluid ofBALB/c nu/nu mice using protein A chromatography as described (14) . Gk1.5, Rat IgG2a, hybridoma specific for CD4 (L3T4), as described (15) , was purchased from American Type Culture Collection, Rockville, MD (TIB 207). Gk1 .5 was used as an ascites fluid obtained from BALB/c nu/nu mice. HO-13-4, MIgM, specific for Thy1.2 T cells, as described (16) , was purchased from American Type Culture Collection (TIB 99) and used as an ascites fluid obtained from BALB/c nu/nu mice.
RCS Tumor and Tumor Purification . The transplantable RCS line, RCS LA-12, used in the present studies arose spontaneously in a female SJL/J mouse and was established as a transplantable line in our laboratory. This tumor was maintained in vivo by intraperitoneal passage of 107 viable cells in young SJL/J mice. Spontaneous primary tumors were obtained from mesenteric lymph nodes of 14-15-mo-old female SJL/J mice. RCS single cell suspensions were made from excised tumorous mesenteric lymph nodes (8-14 d after inoculation for RCS LA-12), and separated from B cells and macrophages on a nylon wool column . T cells were removed by the use of HO-13-4 and low-tox rabbit complement (Cedarlane Laboratories, Hornby, Ontario), 1 :10, followed by isolation of RCS on Ficoll-Hypaque density-gradient centrifugation as previously described (17) .
IL-2 Production by RCS-speck T Cell Hybridomas . RCS-specific T cell hybridomas and the IL-2 production assay were described previously in (10) . Briefly, 2 x 105 hybridoma cells were cocultured with 105 glutaraldehyde-fixed (0.01%) RCS or 106 'Y-irradiated (2,000 rad) SJL/J spleen cells in 200 ul of complete medium at 37°C for 24 h in a humidifying C02 incubator. 50 wl ofsupernatant from each well was transferred to microtiter plates containing 5 x 103 CTLL-2 and incubated at 37°C for 16-20 h. CTLL-2 cells were then pulsed with 1 uCi of [3H]TdR for an additional 8 h, after which cells were MASH harvested onto glass fiber filters (W. A. Bioproducts, Walkersville, MD) and [3H]TdR incorporation was assessed in the presence of 1 .0 ml of Safety-sol II scintillation fluid (Research Products International, Mt. Prospect, IL) using a beta counter.
[3H]TdR incorporation is expressed in cpm t SD.
CTLL-2 Line. The IL-2-dependent CTLL-2 cell line, as described (18) , was purchased from American Type Culture Collection (TIB 214) and maintained in 9 parts complete medium and 1 part rat Con A supernatant as a source of IL-2.
SJL/J Spleen T Cells and the Mixed Lymphocyte Tumor Interaction (MLTI) and MLR Cultures. Splenic T cells from 8-12-wk-old SJL/J mice were purified as described (8) . For MLTI cultures, 5 x 105 SJL/J T cells were incubated with 5 x 10' y-irradiated RCS (10K R) in a total volume of 200 ul complete medium, in 96-well flat bottomed plates . The cultures were then incubated for 96 h at 37°C in a humidifying 10% C02 incubator. A 1.0 gCi pulse of [3H]TdR was added to each well during the last 24 h, after which the plates were MASH harvested and [3H]TdR incorporation was assessed. For MLR cultures, 5 x 105 SJL/J T cells were incubated with 5 x 105 y-irradiated (2,000 rad) autologous SJL/J spleen cells . For fluorocytometric analysis parallel 0.8-ml MLTI cultures were performed in 24-well cluster dishes (Costar, Cambridge, MA) . The viable cells were collected on Ficoll-Hypaque gradients and analyzed after antibody staining by flow cytometer.
mAb Mediated Inhibition ofIL-2 Production by T Cell Hybridomas and T Cell Proliferation. Inhibition assays using affinity-purified monomeric KJ23a were performed analogous to inhibition assays described (10) . Briefly, IL-2 production and T cell proliferation assays were performed as described above, except 10 wg/ml filter-sterilized affinity-purified monomeric KJ23a mAb was added at the initiation ofeach culture . Monomeric KJ23a was obtained by ultracentrifugation of 200 gg/ml affinity-purified KJ23a at 35,000 rpm in an SW50 .1 rotor at 4°C for 1 .5 h. The resulting supernatant was collected and sterilized by filtration through 0 .22 wM filter (Gelman Sciences, Inc ., Ann Arbor, MI) . The nonreactive mAb F23 .1 was treated similarly and added in parallel as a negative control . Inhibition by KJ23a of IL-2 production was expressed relative to the IL-2 production by the hybridomas in the presence of F23 .1 mAb .
Fluorocytometric Analysis. Results RCS Tumor-specific T Cell Hybridomas Express V(317a-bearing 7LR. In a previous study, we have characterized four RCS-specific T cell hybridoma clones (10) . Two hybridomas, IF8-11-2 and 2D5-3-3, were RCS specific and released IL-2 only when cocultured with RCS tumors. The other two hybridomas, 45-2-4 and 1A4-6, released IL-2 when cocultured with RCS or IE+ allogeneic spleen cells . Because of this response to IE-bearing cells, we examined whether the hybridomas were expressing V(317a-bearing TCR . Fluorocytometric analysis revealed that all four T cell hybridomas stained positively with KJ23a (anti Vo17a) and were negative for the control mAb F23.1 (anti V(38) (data not shown). To corroborate these findings, we tested whether monomeric KJ23a mAb would inhibit the RCS-stimulated release of IL-2 by the hybridomas . As seen in Table I (Exp. 1), KJ23a inhibited by >90% the release of IL-2 by the hybridomas in the presence of RCS; F23 .1 had no effect . Furthermore, KJ23a inhibited the allo-stimulatory response of 45-2-4 to DBA/2 spleen cells (Table I, Exp . 2 ) . These results demonstrate that all four RCS-specific T cell hybridomas bear V017a-containing TCR . Furthermore, these results indicated that the same R chain of the TCR is involved in both the RCS and allogeneic response by 45-2-4.
The Syngeneic Proliferative Response, In Vitro, to RCS Is Predominantly Mediated by CD4+ V/317a+ T Cells. To address the role of KJ23a+ T cells in the generation of the syn- Inhibition of RCS-speck T Cell Hybridoma Secretion of IL-2 in the Presence of KJ23a mAb [ 3 H]TdR incorporation as measured with the IL-2-dependent CTLL-2 cell line . CTLL-2 proliferation in the absence of IL-2 was <500 cpm, while in the presence of IL-2 (rat Con A supernatant 1 :10) it was 71,500 cpm . Percent inhibition (in parentheses) by KJ23a of IL-2 production was expressed relative to the IL-2 production by the hybridomas in the presence of F23 .1 mAb .
x RCS LA-12 stimulator cells were fixed with 0 .01 % glutaraldehyde and did not release measurable IL-2 .
S Assay was performed as above, except 10 6 y-irradiated DBA/2 (IEd ) spleen cells were used as stimulator cells . DBA/2 cells alone did not release measurable amounts of IL-2 .
geneic proliferative response to RCS, we performed MI TI cultures in the presence and absence of KJ23a mAb. Syngeneic MLR cultures were maintained in parallel, using autologous spleen cells, as a control for nonspecific proliferation. In the presence of 10 ug/ml of KJ23a mAb, the SJL/J T cell proliferative response was markedly inhibited from 25 to 76% (Table II) . The control F23.1 mAb had no effect . The effective blocking by KJ23a mAb was not restricted to the particular RCS line used, in that the proliferative response of SJL/J T cells to spontaneous primary mesenteric RCS tumors, RCS Sp-3, RCS Sp-4, and RCS Sp-7, was also significantly inhibited by KJ23a ( sponse of T cells to both spontaneous and transplantable RCS, we determined quantitatively the frequency of the responding V017a+ T cells in the T cell blast population . TCRspecific mAb staining was enumerated using PE-coupled goat anti-mouse IgG (red), while the CD4-specific staining was monitored by FITC-conjugated goat anti-rat IgG (green). As seen in Fig. 1 A, the initial T cell population on day 0 was 56% CD4+ T cells (the sum of quadrants 2 and 4) of which 9% were double positive for KJ23a and Gk1.5 (quadrant 2 only). Furthermore, the T cells were of uniform size as determined by forward angle and 90°angle light scatter (data not shown) . However, after 4 d of culture with the transplantable RCS LA-12 line, the T cells were 66% double positive for KJ23a and Gk1.5, when analyzed as a whole population (Fig . 1 B) . Further, if only the blast population was analyzed, the resultant double-labeled T cells represented >80% of the total blast cells (Fig. 1 C) . Moreover, all the Gk1.5 + T cells in the blast population were also KJ23a+ ; thus, virtually all of the CD4+ T cell blasts generated in response to RCS LA-12 were V017a+ T helper cells.
When the MI TI cultures were effected using y-irradiated spontaneous RCS tumors as stimulator cells, we obtained comparable results with those seen using the RCS LA-12 line . As seen in Fig. 2 A, two-color analysis of day 4 T cells cocultured with the spontaneous RCS tumor, RCS Sp-3, shows that 47 % of the total cells were both KJ23a+ and Gk1.5 + . Interestingly, as seen above with T cells cultured with RCS LA-12, two populations of CD4+ T cells were observed after coculture with RCS Sp-3 ; a CD4 dim population, which represented 27% of the total cells (36.4 of the total CD4+ T cells), and a CD4+ bright population, which was 47% of the total cells (63 .5% of the total CD4+ cells) . All of the CD4 bright cells were also KJ23a+, and represented blast cells as judged by forward angle and 90°angle light scatter (data not shown) . These results demonstrate that both spontaneous and transplantable RCS tumors stimulate a similar and marked proliferation of KJ23a+ T cells. Two-color analysis of SJL/J spleen T cells cocultured with RCS tumor. T cells were incubated with KJ23a (mouse IgG2a) and Gkl .5 (rat IgG2a), washed, and then incubated with FITC-conjugated goat anti-rat IgG (F-GAR) to label Gk1.5 and phycoerythrin-conjugated goat anti-mouse IgG (PE-GAM) to label KJ23a. PE-GAM was pre-adsorbed on rat IgG sepharose to remove anti-rat IgG crossreactivity. Control staining and analysis using only the fluorochromeconjugated secondary reagents were performed to set the red and green gains, size gates, and quadrant lines (data not shown) . moved and analyzed by two-color fluorocytometry. As seen in Fig. 2 B, CD4+ T cells represent 51 % of the total cells in the nylon wool-nonadherent fraction (T cells and RCS tumor) . Further, 70% of the CD4+ T cells were also positively stained by KJ23a. This is comparable with the number of V(317a' T cells found in the in vitro MLTI cultures (Fig. 1, B and C) . Furthermore, the KJ23a+ T cells were also brightly stained by Gk1.5 . The remaining dull CD4' T cells (30°Io of the total CD4+ cells) were KJ23a- (Fig . 2 B) . We therefore conclude that V(317a+ T cells play an important role in responding to RCS stimulation in vivo. 
The Responsive Syngeneic RCS-speck T Cells in

Discussion
Evidence is presented here that demonstrates the majority of the syngeneic cells responding to both primary spontaneous RCS tumors and transplantable RCS LA-12 are CD4' V017a' T cells. Several lines of evidence support this conclusion . All four RCS-specific T cell hybridoma clones are V017a' and show marked inhibition of IL-2 release in the presence of KJ23a mAb. Secondly, the response of SJL/J T cells to both spontaneous and transplantable RCS was markedly inhibited by the addition of monomeric KJ23a. The T cell proliferative response was inhibited on average by 54%, despite the fact that VD17a+ T cells represent only 7-9% of the total splenic T cells in SJL/J mice. Third, we analyzed by flow cytometry the SJL/J T cells after a 4-d stimulation by either spontaneous or transplantable RCS, and found significant expansion of the KJ23a* T cells from an input level of 9% to as high as 84% of the total blast population . Concordantly, these cells were bright staining for CD4 (L3T4) . The dim staining L3T4' T cells were devoid of KJ23a+ cells, suggesting that all of the KJ23a+ cells responded to RCS by developing into blast T cells. Lastly, we analyzed the phenotype of T cells from tumor-bearing mesenteric lymph nodes, and found that the majority of the CD4+ T cells responding to RCS were KJ23a* . Therefore, it appears that the in vivo response was comparable with that seen in vitro. These findings represent the first demonstration of a striking expansion of T cells bearing a single VP TCR family in response to a spontaneous tumor. Furthermore, these results support the notion that the RCS tumors carry IE or "IE-Like" tumor-associated antigens .
Kappler et al . (11) found that TCR that use the V017a variable segment gene product react with high frequency to the IE class II MHC molecules. This bias towards IE recognition by V017a' T cells was independent of the coexpressed a chain of the TCR (11) . Further, mice that demonstrate intrathymic expression of IE were shown to selectively delete V017a' cells during T cell maturation (12) . Interestingly, previous studies using F1 hybrid mice from matings of either SJL/J and congenic mice, or SJL/J and recombinant congenic mice found that both the in vivo growth of RCS and the in vitro RCS-specific T cell response correlated inversely with IE expression . In fact, F1 mice that expressed IE failed to grow or respond to the tumor. This negative effect could not be overcome by increasing either tumor inoculum or by increasing the assay periods (7) . Thus, in light of the evidence presented here and that IE-expressing mice debate V(317a+ T Cells, it seems attractive to speculate that the failure of IE-expressing Fl mice to support the growth of and respond to RCS is the result of the deletion of V017a' T cells in these mice .
The predominant role played by VR17a+ T cells in the response to RCS suggests a potential therapeutic role for KJ23a mAb in the intervention and prevention of RCS tumors in SJL/J mice . Treatment of SJL/J mice with KJ23a mAb may result in the complete inhibition of RCS growth . Further, the prophylactic treatment of aged mice with KJ23a may prevent the onset of spontaneous RCS tumors . These approaches, while not radically different from our previous studies using Gk1.5 (5), have several advantages . KJ23a mAb affects only a portion of the CD4 subset and not the whole CD4 population, thereby not crippling the host's ability to mount protective humoral and cellular immunity. Furthermore, unlike Gk1.5, the KJ23a mAb is of mouse origin, which should allow for a slower clearance rate and would not elicit a potentially fatal anti-rat Ig response, as has been seen upon repeated administration of rat IgG. Therefore, KJ23a appears to possess the intriguing potential as a tumor-specific therapeutic strategy in SJL/J mice .
The two RCS-specific hybridomas, 178 and 2D5, shown previously not to be stimulated by allo-IE, were nonetheless KJ23a+ . While we have not observed IL-2 release by IF8 or 2D5 in the presence of a number of allogeneic stimulator cells, IF8 and 2D5 have exhibited specific binding to allo-IE spleen cells (IEd, IE'), which was inhibitable by anti-IE mAb of defined specificities (unpublished observation). We are currently investigating whether the specific binding, while not leading to IL-2 release, may trigger other initial activation events, such as the mobilization of cytoplasmic Cat+ . Further, we have clearly not exhausted all possible allogeneic IE+ strains, therefore, there may still be allogeneic strains that bind and stimulate 1F8 and 2D5. However, the fact that IF8 and 2D5 are KJ23a+ and do not release IL-2 upon stimulation by the allo-IE strains tested to date, still remains an enigma.
While the reactivity of V(317a+ T cells from SJL/J mice to IE appears to be greatest for allogeneic IE, there is a significant reactivity of V017a+ T cells for self IE (19) . SJL/J mice lack expression of the as heterodimer of IE due to a 600-bp deletion in the promoter and leader sequence of the Ea gene (20, 21) . ED, however, is actively transcribed (20) . The nature of the IE-like determinant on SJL/J RCS tumors remains unknown. However, experiments using L cells transfected with Ea and AD genomic DNA have demonstrated that cell surface expression of Ea and AD is possible, in what are termed mixed isotype heterodimers (22, 23) . Therefore, it remains a formal possibility that ED' is expressed with Aas in a mixed heterodimer on the surface of RCS tumors . SJL/J T cells, which are not tolerant to surface expression of ERs, would therefore respond to it . Evidence presented here would suggest that this response would be predominantly by KJ23a+ T cells. Alternatively, cytoplasmic ED' protein, unable to achieve surface expression, is degraded by the RCS tumor cells and presented by IA' in peptide form . While no direct evidence exists that the presentation of ED peptide by IA' would elicit a KJ23a+ T cell response, recent evidence suggests that allo-reactive CTL clones can recognize allo-MHC class I peptide in the context of self-MHC class I, and thereby reconstitute the allogeneic response (24) . Therefore, it remains to be tested whether RCS tumors may process and present ERs in the context of IA'.
Recent evidence suggests that KJ23a+ T cells recognize and respond to IE only when complexed with a B cell-specific peptide (25) . RCS, a B cell tumor, stimulates a vigorous KJ23a+ T cell response, and therefore, may express this B cell stimulatory antigen. The expression of such an antigen by RCS may explain the observed stimulation of RCS-specific T cell clones by activated syngeneic blast B cells (4) . The exact nature, though, of the RCS tumor-associated antigen awaits future experimentation .
Summary
Previous studies have revealed that the reticulum cell sarcoma (RCS) of SJL/J (H-2g, IE -) mice express an "IE-like" stimulatory tumor-associated antigen, the expression of which is requisite for stimulating host T cells necessary for tumor growth . Herein, we present evidence that the predominant T cells raised in the syngeneic response to both spontaneous and transplantable RCS tumors are of the V017a TCR clonotype. The VS17a+ clonotype of T cells has been shown to interact with IE al-logeneic specificities . We demonstrate that all four characterized RCS-specific T cell hybridomas stained positively for the antiVO17a mAb, KJ23a. Additionally, KJ23a, when added to cocultures of the T cell hybridomas and RCS tumors, inhibited the release of IL-2 by the hybridomas . Further, KJ23a was shown to markedly inhibit the proliferation ofSJL/J T cells when cocultured with either spontaneous or transplantable RCS tumor cells . When analyzed by flow cytometry, the T cell blast population raised in response to both spontaneous and transplantable RCS were >80% KJ23a+ . These T cells were brightly stained by the anti-CD4 mAb, Gk1 .5, and, therefore, represent class II-responsive T cells. In corroboration ofthe in vitro data, T cells derived from mesenteric lymph nodes ofRCS tumor-bearing mice had likewise undergone a similar expansion of VS17a+, CD4`T cells. Together, these results indicate that KJ23a+ T cells play an important and predominant role in the response of SJL/J mice to spontaneous RCS tumors and provide further suggestive evidence that the stimulatory antigen(s) on the RCS tumor is IE or an "IE-like" molecule. Significantly, the important role V017a+ T cells play in the response to RCS suggests a potential therapeutic role for KJ23a mAb in the intervention and prevention of RCS tumors in SJL/J mice.
